Determination of SU5416, a novel angiogenesis inhibitor, in human plasma by liquid chromatography
スポンサーリンク
概要
- 論文の詳細を見る
- 2004-06-05
著者
-
Figg W
Clinical Pharmacokinetics Section Medicine Branch National Cancer Institute
-
Fine Howard
Medical Oncology Clinical Research Unit Clinical Pharmacology Research Core Center For Cancer Resear
-
Figg William
Medical Oncology Branch Center For Cancer Research National Cancer Institute
-
Sparreboom A
Clinical Pharmacology Research Core Medical Oncology Branch Center For Cancer Research National Canc
-
TOHNYA Tanyifor
Medical Oncology Clinical Research Unit, Clinical Pharmacology Research Core, Center for Cancer Rese
-
KIM Sonia
Medical Oncology Clinical Research Unit, Clinical Pharmacology Research Core, Center for Cancer Rese
-
DUNN Lara
Medical Oncology Clinical Research Unit, Clinical Pharmacology Research Core, Center for Cancer Rese
-
SPARREBOOM Alex
Medical Oncology Clinical Research Unit, Clinical Pharmacology Research Core, Center for Cancer Rese
-
Tohnya Tanyifor
Medical Oncology Clinical Research Unit Clinical Pharmacology Research Core Center For Cancer Resear
-
Kim Sonia
Medical Oncology Clinical Research Unit Clinical Pharmacology Research Core Center For Cancer Resear
-
Dunn Lara
Medical Oncology Clinical Research Unit Clinical Pharmacology Research Core Center For Cancer Resear
関連論文
- Determination of MS-275, a novel histone deacetylase inhibitor, in human plasma by liquid chromatography-electrospray mass spectrometry
- Quantitative determination of perifosine, a novel alkylphosphocholine anticancer agent, in human plasma by reversed-phase liquid chromatography-electrospray mass spectrometry
- Determination of the heat shock protein 90 inhibitor 17-dimethylaminoethylamino-17-demethoxygeldanamycin in plasma by liquid chromatography-electrospray mass spectrometry
- Determination of CC-5013, an analogue of thalidomide, in human plasma by liquid chromatography-mass spectrometry
- Determination of the cyclic depsipeptide FK228, a histone deacetylase inhibitor, by liquid chromatography-mass spectrometry
- Determination of midazolam in human plasma by liquid chromatography with mass-spectrometric detection
- Determination of the antiangiogenesis agent 2-methoxyestradiol in human plasma by liquid chromatography with ultraviolet detection
- O^6 -Methylguanine-DNA Methyltransferase (MGMT) as a Determinant of Resistance to Camptothecin Derivatives
- Quantitative determination of total and unbound paclitaxel in human plasma following Abraxane treatment
- Determination of irinotecan (CPT-11) and SN-38 in human whole blood and red blood cells by liquid chromatography with fluorescence detection
- Liquid chromatographic determination of irinotecan and three major metabolites in human plasma, urine and feces
- Determination of paclitaxel in human plasma using single solvent extraction prior to isocratic reversed-phase high-performance liquid chromatography with ultraviolet detection
- Determination of irinotecan (CPT-11) and its active metabolite SN-38 in human plasma by reversed-phase high-performance liquid chromatography with fluorescence detection
- Determination of 17-dimethylaminoethylamino-17-demethoxygeldanamycin in human plasma by liquid chromatography with mass-spectrometric detection
- Determination of SU5416, a novel angiogenesis inhibitor, in human plasma by liquid chromatography
- Liquid chromatographic determination of ketoconazole, a potent inhibitor of CYP3A4-mediated metabolism
- Determination of a benzamide histone deacetylase inhibitor, MS-275, in human plasma by liquid chromatography with mass-spectrometric detection
- Determination of the cyclic depsipeptide FK228 in human and mouse plasma by liquid chromatography with mass-spectrometric detection